Author:
Kim Su-Hyun,Hyun Jae-Won,Kim Ho Jin
Funder
National Research Foundation of Korea
Ministry of Science & ICT
Genzyme
Kael-Gemvax
Merck Serono
Teva-Handok
UCB
Bio & Medical Technology Development Program
Ministry of Science & ICT, Republic of Korea
Subject
Cell Biology,Cellular and Molecular Neuroscience
Reference69 articles.
1. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study;Agius;Mult. Scler.,2017
2. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study;Annovazzi;J. Neurol.,2016
3. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponseive to anti-CD20 therapy;Ayzenberg;JAMA Neurol.,2013
4. Impact of rituximab on relapse rate and disability in neuromyelitis optica;Bedi;Mult. Scler.,2011
5. B lymphocytes in neuromyelitis optica;Bennett;Neurol. Neuroimmunol. Neuroinflamm.,2015
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献